La Jolla Pharmaceutical Company (NASDAQ:LJPC) has earned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $55.40.
A number of brokerages have recently weighed in on LJPC. BidaskClub raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $85.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, July 25th. Zacks Investment Research cut La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $57.00 target price on shares of La Jolla Pharmaceutical in a research note on Monday, May 22nd.
COPYRIGHT VIOLATION NOTICE: “La Jolla Pharmaceutical Company (NASDAQ:LJPC) Given Average Rating of “Buy” by Brokerages” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/brokerages-set-la-jolla-pharmaceutical-company-nasdaqljpc-target-price-at-43-17-updated-updated-updated.html.
A number of institutional investors have recently modified their holdings of LJPC. FMR LLC boosted its position in La Jolla Pharmaceutical by 0.6% in the second quarter. FMR LLC now owns 3,313,318 shares of the biopharmaceutical company’s stock valued at $98,637,000 after buying an additional 18,883 shares during the last quarter. Vanguard Group Inc. boosted its position in La Jolla Pharmaceutical by 23.3% in the second quarter. Vanguard Group Inc. now owns 816,779 shares of the biopharmaceutical company’s stock valued at $24,316,000 after buying an additional 154,494 shares during the last quarter. Northern Trust Corp boosted its position in La Jolla Pharmaceutical by 26.4% in the second quarter. Northern Trust Corp now owns 256,640 shares of the biopharmaceutical company’s stock valued at $7,641,000 after buying an additional 53,678 shares during the last quarter. Citigroup Inc. boosted its stake in La Jolla Pharmaceutical by 1,827.3% in the second quarter. Citigroup Inc. now owns 44,077 shares of the biopharmaceutical company’s stock worth $1,313,000 after buying an additional 41,790 shares in the last quarter. Finally, Quantitative Investment Management LLC purchased a new stake in La Jolla Pharmaceutical during the second quarter worth $3,625,000.
La Jolla Pharmaceutical (NASDAQ LJPC) traded up 1.39% on Friday, reaching $30.57. The company had a trading volume of 141,077 shares. The stock’s 50 day moving average is $31.59 and its 200-day moving average is $28.78. The stock’s market capitalization is $676.30 million. La Jolla Pharmaceutical has a 1-year low of $14.63 and a 1-year high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same period last year, the firm earned ($0.90) earnings per share. On average, equities analysts predict that La Jolla Pharmaceutical will post ($4.96) EPS for the current fiscal year.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
What are top analysts saying about La Jolla Pharmaceutical Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for La Jolla Pharmaceutical Company and related companies.